摘要
目的:分析阿糖腺苷联合病毒唑治疗手足口病患儿的疗效。方法:将符合诊断标准的88例手足口病患儿随机为治疗组和对照组,每组各44例。治疗组患儿给予静脉滴注阿糖腺苷(5~10 mg/kg,1次/d)和病毒唑注射液(10 mg/kg,1次/d)治疗;对照组患儿仅给予静脉滴注病毒唑注射液(10 mg/kg,1次/d)治疗。在治疗过程中,两组患儿常规给予液体疗法及对症处理;若患儿合并细菌感染则给予抗生素治疗。两组患儿均在治疗5 d后,观察并比较临床治疗效果。结果:治疗组患儿的疗效明显优于对照组,差异有统计学意义(P〈0.05)。结论:阿糖腺苷联合病毒唑治疗小儿手足口病的疗效可靠,安全,值得临床推广。
Objective: To analyze the curative effects of Vidarabine combined with Ribavirin in treatment of hand,foot and mouth disease. Methods: 88 children with hand,foot and mouth disease conforming to the diagnostic criteria were randomly divided into treatment group( n = 44) and control group( n = 44). The treatment group was intravenously dripped with Vidarabine( 5-10 mg / kg,1 / d),and Ribavirin injection( 10 mg / kg,1 / d),while the control group was only give the intravenous drip of Ribavirin injection( 10 mg / kg,1 / d). Besides,the two groups were given the regular fluid therapy and symptomatic treatment. When the bacterial infections occurred,it should use the antibiotics. 5 days after the treatment,the clinical effects of the two groups were observed. Results: There were statistically significant differences in the curative effects between the two groups( P 〈0. 0). Conclusions: Vidarabine combined with Ribavirin in the treatment of the children with hand,foot and mouth disease has reliable curative effects,and is safe and worthy of clinical promotion.
出处
《中国民康医学》
2016年第23期17-18,共2页
Medical Journal of Chinese People’s Health
关键词
手足口病
阿糖腺苷联合病毒唑
Hand
foot and mouth disease
Vidarabine combined with Ribavirin